Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-930-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$712.97 million
Profitability
Miscellaneous
Employees1,800
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) released its quarterly earnings data on Thursday, February, 21st. The medical device company reported $0.43 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.40 by $0.03. The medical device company earned $195.94 million during the quarter, compared to analyst estimates of $195.50 million. Globus Medical had a net margin of 21.95% and a return on equity of 15.22%. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical updated its FY19 earnings guidance on Thursday, February, 21st. The company provided earnings per share (EPS) guidance of $1.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.72. The company issued revenue guidance of $770 million, compared to the consensus revenue estimate of $767.52 million.Globus Medical also updated its FY 2019 guidance to $1.72-1.72 EPS.
What price target have analysts set for GMED?
10 equities research analysts have issued 1 year price targets for Globus Medical's shares. Their predictions range from $37.00 to $65.00. On average, they expect Globus Medical's stock price to reach $56.20 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for Globus Medical.
What is the consensus analysts' recommendation for Globus Medical?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (3/19/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019)
Has Globus Medical been receiving favorable news coverage?
Press coverage about GMED stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Globus Medical earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include ResMed (RMD), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), ICU Medical (ICUI), Novocure (NVCR), Haemonetics (HAE), Tandem Diabetes Care (TNDM), Merit Medical Systems (MMSI), NuVasive (NUVA) and Glaukos (GKOS).
What other stocks do shareholders of Globus Medical own?
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
- Mr. David M. Demski, CEO & Director (Age 61)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
- Mr. David D. Davidar, Co-Founder & Director (Age 53)
- Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.66%), Investec Asset Management LTD (1.52%), Bank of New York Mellon Corp (1.50%), Oregon Public Employees Retirement Fund (1.27%), Victory Capital Management Inc. (1.24%) and Northern Trust Corp (1.21%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which institutional investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Standard Life Aberdeen plc, Canada Pension Plan Investment Board, Bank of New York Mellon Corp, Gotham Asset Management LLC and Oak Ridge Investments LLC. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, Daniel T Scavilla, David C Paul, David M Demski, Eric Schwartz, James R Tobin and Steven Payne. View Insider Buying and Selling for Globus Medical.
Which institutional investors are buying Globus Medical stock?
GMED stock was acquired by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Oregon Public Employees Retirement Fund, Norges Bank, Legal & General Group Plc, Retirement Systems of Alabama, Squarepoint Ops LLC, Rhumbline Advisers and Kayne Anderson Rudnick Investment Management LLC. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $49.07.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $4.84 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.
What is Globus Medical's official website?
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (NYSE GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
